Alterity Therapeutics Receives Positive FDA Feedback Following Second Type C Meeting on ATH434 Phase 3 Program in Multiple System Atrophy

Alignment reached on chemistry, manufacturing, and control (CMC) elements of ATH434 Phase 3 development program – – Positive feedback supports ...
The Lancet

A step towards disease-modifying therapy for multiple system atrophy

Multiple system atrophy (MSA) is an adult-onset, rapidly progressive neurodegenerative disorder characterised by the aggregation of α-synuclein in oligodendroglial cytoplasmatic inclusions.1 ...

ALTERITY THERAPEUTICS LIMITED: Alterity Therapeutics Receives Positive FDA Feedback Following Second Type C Meeting on ATH434 Phase 3 Program in Multiple System Atrophy

Alignment reached on chemistry, manufacturing, and control (CMC) elements of ATH434 Phase 3 development program - - Positive feedback supports readiness for Phase 3 initiation with manufacturing ...

Alterity Therapeutics to Host Virtual KOL Event to Share New Insights on ATH434 for the Treatment of Multiple System Atrophy

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today ...
The Bakersfield Californian

Alterity Therapeutics Receives Positive FDA Feedback Following Second Type C Meeting on ATH434 ...

Alignment reached on chemistry, manufacturing, and control (CMC) elements of ATH434 Phase 3 development program – – Positive feedback supports readiness for Phase 3 initiation with manufacturing scale ...
TMCnet

AskBio's Viralgen to Supply Commercial-Scale Drug Product for REGENERATE-PD Investigational Gene Therapy Phase II Trial for Parkinson's Disease

Ametefgene parvec (AB-1005) manufactured at Viralgen commercial manufacturing facility with next-generation process to deliver high-purity product with greater efficiency   AskBio Inc. (AskBio), a ...
Pharmabiz

New NIHR Translational Research Collaboration launched in Parkinson's disease

New NIHR Translational Research Collaboration launched in Parkinson's disease: United Kingdom Monday, April 27, 2026, 12:00 Hrs [IST] The NIHR is expanding its Translational Resea ...
American Association of Individual Investors

Why Alterity Therapeutics Limited’s (ATHE) Stock Is Down 8.54%

As of Tuesday, April 21, Alterity Therapeutics Limited’s ATHE share price has dipped by 8.54%, which has investors ...
Medscape

EMA Greenlights Drugs for MS and Spinal Muscular Atrophy

Cenrifki prevents MS disease progression and Itvisma delivers a healthy gene-to-cell nuclei, addressing the root cause of SMA.
BioWorld

Mabwell announces Chinese clinical trial clearance for SST-001

Bioscience Co. Ltd. has announced that SST-001 (18F-FD4), an α-synuclein-targeted PET tracer developed by Mabwell’s incubated company Synusight Biotech, has received clinical trial clearance from ...
Pharmabiz

Galmed announces the breakthrough development of a brain penetrating new formulation of its SCD1 inhibitor, Aramchol

Galmed Pharmaceuticals Ltd. (Galmed), a clinical-stage biopharmaceutical company for liver, cardiometabolic diseases and GI oncological therapeutics, announced the breakthrough development of a brain ...
The Bakersfield Californian

Alterity Therapeutics to Host Virtual KOL Event to Share New Insights on ATH434 for the ...

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments ...